Item 7.01. Regulation FD Disclosure.

On January 10, 2020, Avadel Pharmaceuticals plc (the "Company") updated its corporate presentation for use in meetings with investors, analysts and others. A copy of the updated corporate presentation is furnished herewith as Exhibit 99.1 and incorporated herein by reference. The Company undertakes no obligation to update, supplement or amend the materials furnished herewith as Exhibit 99.1.

The information furnished under this Item 7.01, including Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.




 Item 8.01 Other Events

On January 7, 2020, Exela Pharma Sciences, LLC ("Exela") filed a complaint against the Company and its subsidiary, Avadel Legacy Pharmaceuticals, LLC ("Avadel Legacy") in the United States District for the District of Delaware. The complaint alleged patent infringement by the Company and Avadel Legacy of a certain Exela patent related to its cysteine hydrochloride product. While Avadel Legacy has not yet been served with notice of this complaint, the Company believes it has defenses to any related cause of action and plans to vigorously pursue these defenses in federal court if necessary.





 Item 9.01. Exhibits




(d) Exhibits

99.1 Corporate presentation of Avadel Pharmaceuticals plc, dated January 10, 2020.

© Edgar Online, source Glimpses